China Biotech Services Holdings (HKSE:08037) Total Payout Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08037 China Biotech Services Holdings Ltd HKSE:08037
27 GF Score
Price HK$0.56
GF Value HK$0.26
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is China Biotech Services Holdings Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

China Biotech Services Holdings's current Total Payout Ratio is .

China Biotech Services Holdings Total Payout Ratio Related Terms

China Biotech Services Holdings Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for China Biotech Services Holdings's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Biotech Services Holdings Total Payout Ratio Chart

China Biotech Services Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.01 -0.15 0.02 0.00

China Biotech Services Holdings Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

HKSE:08037 vs TMO, DHR, NTRA: Total Payout Ratio Comparison

For the Diagnostics & Research subindustry, China Biotech Services Holdings's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Biotech Services Holdings Total Payout Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where China Biotech Services Holdings's Total Payout Ratio falls into.


HKSE:08037
27GF Score
China Biotech Services Holdings Ltd HKSE:08037
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Biotech Services Holdings Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

China Biotech Services Holdings's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 0 + -0) / -68.778
=0.00

China Biotech Services Holdings's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- ( + + ) / 18.23
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?

Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued. The current stock price of HK$0.56 is trading 115.4% above its estimated GF Value™ of HK$0.26. GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:08037:

  • Total Payout Ratio:
  • GF Value™: HK$0.26 vs. price of HK$0.56 (115.4% above fair value)
  • GF Score™: 27/100 with 6 warning signs

No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Biotech Services Holdings Business Description

Address 255-257 Gloucester Road, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
27GF Score

Get the complete analysis for HKSE:08037

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.56
Price
HK$0.26
GF Value